The development of integrated positron emission tomography (PET)/ magnetic resonance imaging (MRI) scanners opened a new scenario for cancer diagnosis, treatment, and follow-up. Multimodal imaging combines functional and morphological information from different modalities, which, singularly, cannot provide a comprehensive pathophysiological overview. Molecular imaging exploits multimodal imaging in order to obtain information at a biological and cellular level; in this way, it is possible to track biological pathways and discover many typical tumoral features. In this context, nanoparticle-based contrast agents (CAs) can improve probe biocompatibility and biodistribution, prolonging blood half-life to achieve specific target accumulation and non-toxicity. In addition, CAs can be simultaneously delivered with drugs or, in general, therapeutic agents gathering a dual diagnostic and therapeutic effect in order to perform cancer diagnosis and treatment simultaneous. The way for personalized medicine is not so far. Herein, we report principles, characteristics, applications, and concerns of nanoparticle (NP)-based PET/MRI CAs.

Radiolabeled PET/MRI Nanoparticles for Tumor Imaging / Forte, Ernesto; Fiorenza, Dario; Torino, Enza; Costagliola di Polidoro, Angela; Cavaliere, Carlo; Netti, Paolo A; Salvatore, Marco; Aiello, Marco. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:1(2020), p. 89. [10.3390/jcm9010089]

Radiolabeled PET/MRI Nanoparticles for Tumor Imaging

Torino, Enza
;
Costagliola di Polidoro, Angela;Cavaliere, Carlo;Netti, Paolo A;Aiello, Marco
2020

Abstract

The development of integrated positron emission tomography (PET)/ magnetic resonance imaging (MRI) scanners opened a new scenario for cancer diagnosis, treatment, and follow-up. Multimodal imaging combines functional and morphological information from different modalities, which, singularly, cannot provide a comprehensive pathophysiological overview. Molecular imaging exploits multimodal imaging in order to obtain information at a biological and cellular level; in this way, it is possible to track biological pathways and discover many typical tumoral features. In this context, nanoparticle-based contrast agents (CAs) can improve probe biocompatibility and biodistribution, prolonging blood half-life to achieve specific target accumulation and non-toxicity. In addition, CAs can be simultaneously delivered with drugs or, in general, therapeutic agents gathering a dual diagnostic and therapeutic effect in order to perform cancer diagnosis and treatment simultaneous. The way for personalized medicine is not so far. Herein, we report principles, characteristics, applications, and concerns of nanoparticle (NP)-based PET/MRI CAs.
2020
Radiolabeled PET/MRI Nanoparticles for Tumor Imaging / Forte, Ernesto; Fiorenza, Dario; Torino, Enza; Costagliola di Polidoro, Angela; Cavaliere, Carlo; Netti, Paolo A; Salvatore, Marco; Aiello, Marco. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:1(2020), p. 89. [10.3390/jcm9010089]
File in questo prodotto:
File Dimensione Formato  
jcm-09-00089-v2 (1).pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Dominio pubblico
Dimensione 1.39 MB
Formato Adobe PDF
1.39 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/831033
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 48
social impact